GlobalData

The tauopathies market, which covers more than 20 neurodegenerative diseases such as progressive

The company's latest report states that once the first drug in the tauopathies market is approve

Akiko Fukui, MSc, Healthcare Analyst for GlobalData, explains: "There are currently no approved thera

"The first drug will set an example for effective mechanisms of action (MOAs), regulatory processes, ar

If a disease-modifying approach is approved, patients' lives will be extended and this will provide a bas

Fukui continues: "The possibility of expanding sales from the tauopathies market into the much larger A

GlobalData has identified four products in the late-stage pipeline that are currently in development as t